| ID | Type | Location (GRCh37) | Location (GRCh38) | Length | GC content |
|---|---|---|---|---|---|
| hsa_ELP3_0002800 | Exon-Exon | chr8:27970536-28048669 | chr8:28113019-28191152 | 2609 nt | 0.4653 |
| hsa_ELP3_0004100 | Exon-Exon | chr8:27987019-27995408 | chr8:28129502-28137891 | 483 nt | 0.4803 |
| hsa_ELP3_0004200 | Exon-Exon | chr8:27987019-28019595 | chr8:28129502-28162078 | 950 nt | 0.4695 |
| hsa_ELP3_0004600 | Exon-Exon | chr8:27995215-28019595 | chr8:28137698-28162078 | 661 nt | 0.4720 |
| hsa_ELP3_0005200 | Exon-Exon | chr8:28013459-28013549 | chr8:28155942-28156032 | 91 nt | 0.4615 |
| hsa_ELP3_0005300 | Exon-Exon | chr8:28013459-28019595 | chr8:28155942-28162078 | 467 nt | 0.4582 |
| hsa_ELP3_0000100 | Exon-Exon | chr8:27954736-27957483 | chr8:28097219-28099966 | 239 nt | 0.4979 |
| hsa_ELP3_0000200 | Exon-Exon | chr8:27954736-27989921 | chr8:28097219-28132404 | 106 nt | 0.4340 |
| hsa_ELP3_0000300 | Exon-Exon | chr8:27954736-28019595 | chr8:28097219-28162078 | 182 nt | 0.4505 |
| hsa_ELP3_0000700 | Exon-Exon | chr8:27957345-27967955 | chr8:28099828-28110438 | 208 nt | 0.5240 |
A study in human bladder cancer demonstrated that the circELP3 contributes to cancer progression and cisplatin resistance [Huang et al. DOI:10.3390/cells11091381].